Aprecia COO Kyle Smith Outlines Challenges of Transitioning to 100 Percent U.S.-Based Pharmaceutical Manufacturing

Aprecia President and Chief Operating Officer Kyle Smith recently outlined the operational landscape for companies attempting to transition to 100 percent United States-based manufacturing. The assessment highlights the logistical and economic hurdles domestic firms encounter when attempting to source active pharmaceutical ingredients (APIs) and raw materials exclusively from within the country.

The report details specific supply chain complexities that complicate the localization of production. Smith notes that while domestic manufacturing offers potential benefits, manufacturers frequently struggle to secure consistent access to necessary chemical components and specialized materials from local suppliers. These challenges often stem from existing global dependencies and the current infrastructure limitations within the U.S. market. Consequently, companies must navigate these procurement obstacles while balancing the requirements of domestic production mandates.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: June 22, 2026

Author

GOAI